Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Updates on DREAMM-6 and DREAMM-2 in R/R myeloma

Rakesh Popat • 12 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Dexamethasone Selinexor
DREAMM-2 DREAMM-6

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, discusses the safety and tolerability of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, in combination with bortezomib/dexamethasone in relapsed/refractory (R/R) multiple myeloma patients as evaluated in the DREAMM-6 study (NCT03544281) as well against selinexor and dexamethasone as evaluated in the DREAMM-2 study (NCT03525678). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals